CIPHER PHARMACEUTICALS INC (CPH.CA) Stock Fundamental Analysis
Canada - Toronto Stock Exchange - TSX:CPH - CA17253X1050 - Common Stock
14.86 CAD
-0.09 (-0.6%)
We assign a fundamental rating of 7 out of 10 to CPH. CPH was compared to 33 industry peers in the Pharmaceuticals industry. CPH has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. CPH is not priced too expensively while it is growing strongly. Keep and eye on this one! These ratings could make CPH a good candidate for growth and quality investing.
1. Profitability
1.1 Basic Checks
- In the past year CPH was profitable.
- CPH had a positive operating cash flow in the past year.
- CPH had positive earnings in each of the past 5 years.
- In the past 5 years CPH always reported a positive cash flow from operatings.
1.2 Ratios
- The Return On Assets of CPH (11.77%) is better than 90.91% of its industry peers.
- CPH's Return On Equity of 15.23% is amongst the best of the industry. CPH outperforms 87.88% of its industry peers.
- The Return On Invested Capital of CPH (7.23%) is better than 87.88% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for CPH is in line with the industry average of 8.78%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.77% | ||
| ROE | 15.23% | ||
| ROIC | 7.23% |
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
1.3 Margins
- CPH has a Profit Margin of 34.68%. This is amongst the best in the industry. CPH outperforms 100.00% of its industry peers.
- In the last couple of years the Profit Margin of CPH has grown nicely.
- Looking at the Operating Margin, with a value of 25.51%, CPH belongs to the top of the industry, outperforming 87.88% of the companies in the same industry.
- CPH's Operating Margin has declined in the last couple of years.
- With an excellent Gross Margin value of 74.32%, CPH belongs to the best of the industry, outperforming 93.94% of the companies in the same industry.
- In the last couple of years the Gross Margin of CPH has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 25.51% | ||
| PM (TTM) | 34.68% | ||
| GM | 74.32% |
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), CPH is destroying value.
- The number of shares outstanding for CPH has been increased compared to 1 year ago.
- The number of shares outstanding for CPH has been reduced compared to 5 years ago.
- CPH has a worse debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 6.40 indicates that CPH is not in any danger for bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 6.40, CPH belongs to the top of the industry, outperforming 93.94% of the companies in the same industry.
- The Debt to FCF ratio of CPH is 0.45, which is an excellent value as it means it would take CPH, only 0.45 years of fcf income to pay off all of its debts.
- CPH's Debt to FCF ratio of 0.45 is amongst the best of the industry. CPH outperforms 93.94% of its industry peers.
- CPH has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.
- Looking at the Debt to Equity ratio, with a value of 0.12, CPH is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | 0.45 | ||
| Altman-Z | 6.4 |
ROIC/WACC0.86
WACC8.46%
2.3 Liquidity
- A Current Ratio of 1.30 indicates that CPH should not have too much problems paying its short term obligations.
- CPH has a worse Current ratio (1.30) than 66.67% of its industry peers.
- A Quick Ratio of 0.98 indicates that CPH may have some problems paying its short term obligations.
- CPH has a Quick ratio (0.98) which is comparable to the rest of the industry.
- The current and quick ratio evaluation for CPH is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.3 | ||
| Quick Ratio | 0.98 |
3. Growth
3.1 Past
- The Earnings Per Share has been growing slightly by 4.76% over the past year.
- Measured over the past years, CPH shows a quite strong growth in Earnings Per Share. The EPS has been growing by 12.97% on average per year.
- The Revenue has grown by 89.17% in the past year. This is a very strong growth!
- The Revenue has been growing by 8.25% on average over the past years. This is quite good.
EPS 1Y (TTM)4.76%
EPS 3Y14.06%
EPS 5Y12.97%
EPS Q2Q%2000%
Revenue 1Y (TTM)89.17%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%23.75%
3.2 Future
- CPH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.66% yearly.
- Based on estimates for the next years, CPH will show a very strong growth in Revenue. The Revenue will grow by 27.91% on average per year.
EPS Next Y51.5%
EPS Next 2Y16.2%
EPS Next 3Y20.66%
EPS Next 5YN/A
Revenue Next Year50.96%
Revenue Next 2Y26.89%
Revenue Next 3Y27.91%
Revenue Next 5YN/A
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 16.33, the valuation of CPH can be described as correct.
- CPH's Price/Earnings ratio is rather cheap when compared to the industry. CPH is cheaper than 81.82% of the companies in the same industry.
- The average S&P500 Price/Earnings ratio is at 27.32. CPH is valued slightly cheaper when compared to this.
- With a Price/Forward Earnings ratio of 17.34, CPH is valued on the expensive side.
- Based on the Price/Forward Earnings ratio, CPH is valued a bit cheaper than 69.70% of the companies in the same industry.
- When comparing the Price/Forward Earnings ratio of CPH to the average of the S&P500 Index (24.30), we can say CPH is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.33 | ||
| Fwd PE | 17.34 |
4.2 Price Multiples
- The rest of the industry has a similar Enterprise Value to EBITDA ratio as CPH.
- 78.79% of the companies in the same industry are more expensive than CPH, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.14 | ||
| EV/EBITDA | 14.12 |
4.3 Compensation for Growth
- CPH's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- CPH has an outstanding profitability rating, which may justify a higher PE ratio.
- CPH's earnings are expected to grow with 20.66% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.32
PEG (5Y)1.26
EPS Next 2Y16.2%
EPS Next 3Y20.66%
5. Dividend
5.1 Amount
- No dividends for CPH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TSX:CPH (1/21/2026, 7:00:00 PM)
14.86
-0.09 (-0.6%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)03-16 2026-03-16
Inst Owners1.29%
Inst Owner ChangeN/A
Ins Owners3.62%
Ins Owner ChangeN/A
Market Cap377.00M
Revenue(TTM)50.05M
Net Income(TTM)17.36M
Analysts80
Price Target19.58 (31.76%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)51.24%
Min EPS beat(2)36.14%
Max EPS beat(2)66.34%
EPS beat(4)2
Avg EPS beat(4)14.52%
Min EPS beat(4)-37.21%
Max EPS beat(4)66.34%
EPS beat(8)5
Avg EPS beat(8)34.73%
EPS beat(12)9
Avg EPS beat(12)113.55%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.76%
Min Revenue beat(2)-6.01%
Max Revenue beat(2)2.48%
Revenue beat(4)1
Avg Revenue beat(4)-1.18%
Min Revenue beat(4)-6.01%
Max Revenue beat(4)2.48%
Revenue beat(8)2
Avg Revenue beat(8)-0.16%
Revenue beat(12)3
Avg Revenue beat(12)1.53%
Revenue beat(16)3
Avg Revenue beat(16)-1.19%
PT rev (1m)6.52%
PT rev (3m)9.59%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.06%
EPS NY rev (1m)0%
EPS NY rev (3m)-24.59%
Revenue NQ rev (1m)0.79%
Revenue NQ rev (3m)-5.54%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.24%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.33 | ||
| Fwd PE | 17.34 | ||
| P/S | 5.46 | ||
| P/FCF | 9.14 | ||
| P/OCF | 9.11 | ||
| P/B | 2.4 | ||
| P/tB | 11.96 | ||
| EV/EBITDA | 14.12 |
EPS(TTM)0.91
EY6.12%
EPS(NY)0.86
Fwd EY5.77%
FCF(TTM)1.63
FCFY10.95%
OCF(TTM)1.63
OCFY10.98%
SpS2.72
BVpS6.19
TBVpS1.24
PEG (NY)0.32
PEG (5Y)1.26
Graham Number11.26
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.77% | ||
| ROE | 15.23% | ||
| ROCE | 10.05% | ||
| ROIC | 7.23% | ||
| ROICexc | 7.75% | ||
| ROICexgc | 33.36% | ||
| OM | 25.51% | ||
| PM (TTM) | 34.68% | ||
| GM | 74.32% | ||
| FCFM | 59.76% |
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
ROICexc(3y)14.84%
ROICexc(5y)25.78%
ROICexgc(3y)32.35%
ROICexgc(5y)N/A
ROCE(3y)11.69%
ROCE(5y)20.72%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-55.02%
ROICexc growth 5Y-33.6%
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
F-Score7
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | 0.45 | ||
| Debt/EBITDA | 0.67 | ||
| Cap/Depr | 1.2% | ||
| Cap/Sales | 0.17% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 152.24% | ||
| Profit Quality | 172.34% | ||
| Current Ratio | 1.3 | ||
| Quick Ratio | 0.98 | ||
| Altman-Z | 6.4 |
F-Score7
WACC8.46%
ROIC/WACC0.86
Cap/Depr(3y)670.82%
Cap/Depr(5y)415.05%
Cap/Sales(3y)80.33%
Cap/Sales(5y)48.9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.76%
EPS 3Y14.06%
EPS 5Y12.97%
EPS Q2Q%2000%
EPS Next Y51.5%
EPS Next 2Y16.2%
EPS Next 3Y20.66%
EPS Next 5YN/A
Revenue 1Y (TTM)89.17%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%23.75%
Revenue Next Year50.96%
Revenue Next 2Y26.89%
Revenue Next 3Y27.91%
Revenue Next 5YN/A
EBIT growth 1Y29.19%
EBIT growth 3Y-15.61%
EBIT growth 5Y-7.36%
EBIT Next Year138.84%
EBIT Next 3Y50.52%
EBIT Next 5YN/A
FCF growth 1Y98.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y99.32%
OCF growth 3Y12.28%
OCF growth 5Y19.77%
CIPHER PHARMACEUTICALS INC / CPH.CA FAQ
What is the ChartMill fundamental rating of CIPHER PHARMACEUTICALS INC (CPH.CA) stock?
ChartMill assigns a fundamental rating of 7 / 10 to CPH.CA.
What is the valuation status for CPH stock?
ChartMill assigns a valuation rating of 6 / 10 to CIPHER PHARMACEUTICALS INC (CPH.CA). This can be considered as Fairly Valued.
What is the profitability of CPH stock?
CIPHER PHARMACEUTICALS INC (CPH.CA) has a profitability rating of 8 / 10.
What are the PE and PB ratios of CIPHER PHARMACEUTICALS INC (CPH.CA) stock?
The Price/Earnings (PE) ratio for CIPHER PHARMACEUTICALS INC (CPH.CA) is 16.33 and the Price/Book (PB) ratio is 2.4.
How financially healthy is CIPHER PHARMACEUTICALS INC?
The financial health rating of CIPHER PHARMACEUTICALS INC (CPH.CA) is 7 / 10.